ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "anti-TNF therapy"

  • Abstract Number: 077 • 2020 Pediatric Rheumatology Symposium

    Tubulointerstitial Nephritis and Uveitis (TINU): A Pediatric Case Series with Longitudinal Followup

    Deborah Stein 1, Elizabeth Benoit 1 and Mindy Lo1, 1Boston Children's Hospital, Boston

    Background/Purpose: Tubulointerstitial nephritis and uveitis (TINU) syndrome is an uncommon condition that is likely under-recognized. The ideal treatment of both renal and ophthalmologic disease activity…
  • Abstract Number: 101 • 2020 Pediatric Rheumatology Symposium

    Uveitis Treatment in the CARRA II Registry: Tumor Necrosis Factor-inhibitors and Beyond

    Mona Riskalla1, Fatima Barbar-Smiley 2, Michael Shyne 1 and Melissa Lerman 3, 1University of Minnesota, Minneapolis, Minnesota, 2Nationwide Children's Hospital, Columbus, Ohio, 3Philadelphia, Pennsylvania

    Background/Purpose: Uveitis associated with JIA (JIA-U) is the most common extra-articular complication of JIA. As JIA-U is associated with significant risk of visual loss and…
  • Abstract Number: 136 • 2020 Pediatric Rheumatology Symposium

    Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center

    Sarah Kodama1, Deepti Gupta 2, Erin Sullivan 3 and Yongdong Zhao 4, 1School of Medicine, Virginia Commonwealth University, Richmond, 2Pediatric Dermatology, School of Medicine, University of Washington, Seattle, 3Seattle Children's Research Institute, Seattle, 4University of Washington, Seattle

    Background/Purpose: Paradoxical psoriasis after exposure to tumor necrosis factor inhibitors (TNFi) has been increasingly reported in the adult population. Systematic studies in pediatric population are…
  • Abstract Number: 564 • 2019 ACR/ARP Annual Meeting

    ASDAS Is More Important Than BASDAI in Advanced Ankylosing Spondylitis

    Jae-Bum Jun1, Bon San Koo 2, Seunghun Lee 3, Jinju Kim 4, Juyeon Kang 1 and Tae-Hwan Kim 1, 1Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 2Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea, 3Dertment of Radiology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 4Novartis Korea Ltd., Seoul

    Background/Purpose: In patients with ankylosing spondylitis, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used to measure disease activity to initiate or maintain TNF…
  • Abstract Number: 1446 • 2019 ACR/ARP Annual Meeting

    Golimumab as First, Second or at Least Third Biologic Agent in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Post Hoc Analysis of a Non-Interventional Study in Germany

    Klaus Krüger 1, Gerd Burmester 2, Siegfried Wassenberg 3, Astrid Thiele 4 and Matthias Thomas5, 1Medical Centre of Rheumatology, Munich, Germany, 2Charité—University Medicine Berlin, Berlin, Germany, 3Centre of Rheumatology, Ratingen, Germany, 4Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, 5MSD Sharp & Dohme GmbH, Haar, Germany

    Background/Purpose: The aim of this post hoc analysis is to assess effectiveness of GLM used as first, second, or at least third biologic agent in…
  • Abstract Number: 2768 • 2019 ACR/ARP Annual Meeting

    Changes in B Cell Profile as a Marker of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis

    Borja Hernández-Breijo1, Israel Nieto-Gañán 2, Cristina Sobrino 3, Victoria Navarro-Compán 4, Ana Martínez-Feito 5, Carlota García-Hoz 6, Paloma Lapuente-Suanzes 2, javier Bachiller 3, Gema Bonilla 7, Cristina Pijoán-Moratalla 3, Garbiñe Roy 2, Mónica Vázquez Díaz 3, Alejandro Balsa 7, Luisa María Villar 2, Dora Pascual-Salcedo 1, Eulalia Rodríguez-Martín 2 and Chamaida Plasencia 7, 1Immuno-Rheumatology Research Group, IdiPAZ. La Paz University Hospital, Madrid, Spain, 2Immunology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, Spain, 3Rheumatology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, Spain, 4University Hospital La Paz, IdiPaz, Madrid, Spain, 5Immuno-Rheumatology Research Group, IdiPAZ & Immunology Department. La Paz University Hospital, MADRID, Spain, 6Immunology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, 7Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain

    Background/Purpose: According to the EULAR recommendations, the therapeutic objective in patients with rheumatoid arthritis (RA) should be remission. Biological therapies, as TNF inhibitors (TNFi), have…
  • Abstract Number: 571 • 2019 ACR/ARP Annual Meeting

    Effect of Long-term Treatment with TNF-α Inhibitor on Lipid Profile in Spondyloarthritis: Data from Nationwide Korean College of Rheumatology Biologics (KOBIO) Registry

    Jina Yeo1, Mi Ryoung Seo 1, Hee Jung Ryu 1, Hyo-Jin Choi 1 and Han Joo Baek 1, 1Division of Rheumatology / Department of Internal Medicine / Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea

    Background/Purpose: In spondyloarthritis (SpA), the lipid profile changes due to the systemic inflammatory response. Theoretically, the proinflammatory state is associated with a decrease in total…
  • Abstract Number: 1476 • 2019 ACR/ARP Annual Meeting

    Impact of Alternate Mechanism of Action Biologics and Tofacitinib on TNF-α Inhibitor Prescribing in Psoriatic Arthritis: Results from Annual National Patient Chart Audits

    Lynn Price1, Phil Pouliot 1 and Lauren Schmitt 1, 1Spherix Global Insights, Exton, PA

    Background/Purpose: TNF-α inhibitor therapy has long been the standard of care for adult patients diagnosed with moderate to severe psoriatic arthritis (PsA), though several new…
  • Abstract Number: 2856 • 2019 ACR/ARP Annual Meeting

    Drug Retention of Biological DMARDs Targeting IL-12/IL-23 or IL-17 versus TNF Inhibitors, After a First Line TNF Inhibitor, in Patients with Psoriatic Arthritis – an Analysis in the Swiss SCQM Register

    Burkhard Moeller1, Eleftherios Papagiannoulis 2, Lisa Christ 3, Adrian Ciurea 4, Thomas Hugle 5, Ruediger B. Mueller 6, Michael J. Nissen 7, Almut Scherer 8, Godehard Scholz 3, Peter M. Villiger 1 and Nikhil Yawalkar 3, 1University Hospital Bern, Bern, Switzerland, 2SCQM Zurich, Zurich, Switzerland, 3Inselspital-University Hospital Bern, Bern, Switzerland, 4University Hospital Zürich, Zürich, Switzerland, 5University Hospital Lausanne, Lausanne, Switzerland, 6Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Aargau, Switzerland, 7University Hospital Geneva, Geneva, Switzerland, 8SCQM Foundation, Zürich, Switzerland

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) were the first approved biological disease modifying antirheumatic drugs (bDMARDs) for psoriatic arthritis (PsA). IL-12/23 and IL-17-specific antibodies provide…
  • Abstract Number: 581 • 2019 ACR/ARP Annual Meeting

    Allograft Inflammatory factor-1 Drives Th17 Like Pathologic Signature and Predict Poor Response to TNF Inhibitor in Ankylosing Spondylitis

    Jeong Seok Lee1, Eunyoung Lee 2, Ji Yong Choi 3, Yeong-Wook Song 4, Eui-Cheol Shin 1 and Eun Young Lee 2, 1Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea, 2Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Republic of Korea, 3Seoul National University College of Medicine, Seoul, Republic of Korea, 4Seoul National University Hospital, Seoul, Republic of Korea

    Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory disease that commonly treated with TNF inhibitors for controlling active inflammation. To predict treatment response to TNF inhibitors…
  • Abstract Number: 1499 • 2019 ACR/ARP Annual Meeting

    Golimumab Persistence in Biologic Naive and Non-Naive Patients with Axial Spondyloarthritis: Results of the GO PRACTICE Study

    René-Marc Flipo 1, Florence Tubach 2, Jean Ouaniche 3, Philippe Goupille4, Eric Lespessailles 5, Najat Gouyette 6, Naoual Harid 7, Jean-Marie Fayette 8, Philippe Bertin 9 and Bruno Fautrel 10, 1Roger Salengro University-Hospital, Lille , France, Lille, France, 2Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France, 3Private Practice , Toulon, France, Toulon, France, 4Tours University-Hospital, Tours, France, Tours, France, 5Orléans Regional Hospitals, Orléans ,France, Orléans, France, 6MSD France, Courbevoie ,France, Courbevoie, Ile-de-France, France, 7MSD France, Courbevoie, France, Courbevoie, Ile-de-France, France, 8ClinSearch, Malakoff, France, Malakoff, Ile-de-France, France, 9Limoges University-Hospital , Limoges, France, Limoges, France, 10Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France

    Background/Purpose: The pivotal GO AFTER study [1] and the ongoing observational GO BEYOND study investigate GLM efficacy in rheumatoid arthritis (RA) patients who previously received…
  • Abstract Number: 2857 • 2019 ACR/ARP Annual Meeting

    Decision Tree Analysis to Identify Inflammatory Arthritis Patient Subgroups with Different Levels of Treatment Persistence with First-Line Subcutaneous TNF-alpha Inhibitors

    Emma Hernlund 1, Johan Klint 1, Axel Svedbom 1, Johan Dalén 1, Christopher Black 2 and Amy Puenpatom2, 1ICON plc, Stockholm, Sweden, Stockholm, Sweden, 2Merck & Co., Inc., Kenilworth, NJ, United States, Kenilworth, NJ

    Background/Purpose: The advent of biologic medications, such as subcutaneous TNF-alpha inhibitors (SC-TNFi), has transformed the management of inflammatory arthritis (IA) during the last decades. However,…
  • Abstract Number: 619 • 2019 ACR/ARP Annual Meeting

    Relation of Therapies for Ankylosing Spondylitis to Risk of Total Hip and Knee Arthroplasty

    Rachael Stovall1, Christine Peloquin 2, David Felson 3, Tuhina Neogi 2 and Maureen Dubreuil 4, 1Boston Medical Center, Boston, MA, 2Boston University School of Medicine, Boston, MA, 3Boston University School of Medicine, Department of Rheumatology, Boston, 4Boston University School of Medicine, Boston

    Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory arthritis that predominantly affects the axial skeleton, but commonly affects peripheral joints as well. Peripheral joint involvement often…
  • Abstract Number: 1512 • 2019 ACR/ARP Annual Meeting

    Retention Rates and Response of Anti-TNF Treatments in the Enteropathic Spondylitis: HUR-BIO Real Life Results

    Gozde Kubra Yardımcı 1, Bayram Farisoğulları 1, Alper Sarı 1, Levent Kilic 2, Berkan Armagan 3, Emre Bilgin 1, Ertugrul Cagri Bolek 1, Omer Karadag 4, Ali Akdoğan 1, Şule Apras Bilgen 2, Ali İhsan Ertenli 1, Sedat Kiraz 2 and Umut Kalyoncu5, 1Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, 2Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 3Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey., Ankara, Turkey, 4Hacettepe University Vasculitis Centre, Ankara, Turkey / Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Ankara, Turkey, 5Hacettepe University Department of Rheumatology, Ankara, Turkey

    Background/Purpose: Enteropathic spondylitis (eSpA) is younger brother of spondyloarthritis, and the retention rate of biological DMARD in eSpA was not yet clear.  The objective of this study was to…
  • Abstract Number: 2873 • 2019 ACR/ARP Annual Meeting

    Antimicrobial Use Is High in Patients with Rheumatoid Arthritis, and Further Increases with First-Line TNFi Therapy – Nationwide Results from Iceland

    Aron H Bjornsson1, Olafur Palsson 2, Mar Kristjansson 3, Petur S Gunnarsson 4, Gerdur Grondal 5, Bjorn Gudbjornsson 6 and Thorvardur J Love 7, 1Department of Medicine, Landspitali, Reykjavík, Iceland, 2Department of Clinical Sciences Lund, Lund University and Skåne University Hospital, Lund, Sweden, 3Department of Infectious Diseases, Landspitali, Reykjavík, Iceland, 4Faculty of Pharmaceutical Sciences, University of Iceland and Hospital Pharmacy, Landspitali, Reykjavík, Iceland, 5Department of Rheumatology, Landspitali and Centre for Rheumatology Research, Landspitali, Reykjavík, Iceland, 6Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 7Faculty of Medicine, University of Iceland and Department of Science, Landspitali, Reykjavík, Iceland

    Background/Purpose: Severe infections, frequently resulting in hospitalization, are a well-known adverse effects of tumor necrosis factor inhibitors (TNFi). However, studies regarding outpatient treated infections are…
  • 1
  • 2
  • 3
  • …
  • 29
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies